» Articles » PMID: 15670040

Analysis of MRNA in Hemophilia A Patients with Undetectable Mutations Reveals Normal Splicing in the Factor VIII Gene

Overview
Publisher Elsevier
Specialty Hematology
Date 2005 Jan 27
PMID 15670040
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

Background: haemophilia A (HA) is characterized by partial or total deficiency of factor VIII (FVIII) protein activity. It is caused by a broad spectrum of mutations in the FVIII gene. Despite tremendous improvements in mutation screening methods, in about 2% of HA patients no DNA change could be found, even after sequencing the whole coding part of the FVIII gene including the flanking splice sites, as well as the promotor and the 3' UTR regions.

Objectives, Patients And Methods: In the present study we performed a detailed RNA analysis of three groups of patients. The first included control patients with known splicing defects, the second included two patients with already identified nucleotide changes close to splicing sites, that could potentially alter the normal splicing process, and a third group of 11 unrelated patients whose genomic DNA have already been screened for mutations by DHPLC and direct sequencing with no mutation being identified.

Results: Both candidate splice site mutations were shown to result in either skipping or alternative splicing of at least one exon, therefore these DNA changes must be considered as causal for the patients' HA phenotype. In contrast, no abnormalities on the RNA level were observed in any of 11 unrelated patients without mutations in the FVIII gene.

Conclusions: These findings exclude mutations that could be located deep in the introns and affecting either normal splicing or lead to mechanisms causing some unknown rearrangements of the FVIII gene. In fact, our results point to the presence of still unknown factor(s) causing HA, which might be either allelic or in the close proximity of the FVIII gene or non-allelic associated with other genetic loci that are involved in the processing of the FVIII protein.

Citing Articles

Factor VIII as a Novel Biomarker for Diagnosis, Prognosis, and Therapy Prediction in Human Cancer and Other Disorders.

Khalilian S, Mohajer Z, Ghafouri-Fard S Avicenna J Med Biotechnol. 2024; 16(2):68-80.

PMID: 38618505 PMC: 11007370. DOI: 10.18502/ajmb.v16i2.14857.


Spectrum of Causative Mutations in Patients with Hemophilia A in Russia.

Pshenichnikova O, Salomashkina V, Poznyakova J, Selivanova D, Chernetskaya D, Yakovleva E Genes (Basel). 2023; 14(2).

PMID: 36833187 PMC: 9957479. DOI: 10.3390/genes14020260.


Silent variant in F8:c.222G>T (p.Thr74Thr) causes a partial exon skipping in a patient with mild hemophilia A.

Letelier A, Ljung R, Olsson A, Andersson N Mol Genet Genomic Med. 2021; 10(1):e1856.

PMID: 34962362 PMC: 8801133. DOI: 10.1002/mgg3.1856.


Current therapeutic approaches in the management of hemophilia-a consensus view by the Romanian Society of Hematology.

Hotea I, Brinza M, Blag C, Zimta A, Dirzu N, Burzo C Ann Transl Med. 2021; 9(13):1091.

PMID: 34423003 PMC: 8339806. DOI: 10.21037/atm-21-747.


Therapeutic Modulation of RNA Splicing in Malignant and Non-Malignant Disease.

Marabti E, Abdel-Wahab O Trends Mol Med. 2021; 27(7):643-659.

PMID: 33994320 PMC: 8238868. DOI: 10.1016/j.molmed.2021.04.005.